Significant barriers to HD therapy include limited knowledge on molecular mechanisms implicated by the Huntington protein (HTT), extra-striatal atrophy throughout disease progression, and its broad impact on multiple systems, thus necessitating a systemic approach to treatment. This evidence concerns the gene HTT and Huntington disease.